A1c 9.3% with CKD and Prior MI: What to Change First and What to Stop
58-year-old man with type 2 diabetes for 9 years attends for worsening control. He had an anterior myocardial infarction in 2021 and has stage 3b chronic kidney disease (eGFR 42 mL/min/1.73 m², urine albumin-to-creatinine ratio 380 mg/g). Medications: metformin 1000 mg twice daily, atorvastatin 40 mg, aspirin 81 mg, metoprolol succinate 50 mg, lisinopril 20 mg. BP 136/82 mmHg, BMI 34 kg/m², HbA1c 9.3%. He has had no hypoglycemia and no heart failure symptoms. Potassium is 4.6 mEq/L, there is no peripheral edema, and he is reluctant to add injections, asking why he cannot simply "take a stronger pill."
1. List the next three medication changes in priority order, with the reasoning for each.
Read the worked answer
1. Start an SGLT2 inhibitor (dapagliflozin 10 mg daily) - do not wait on A1c. With prior myocardial infarction, albuminuric CKD, and eGFR 42, he has two independent indications for cardiorenal protection. Glucose-lowering efficacy is blunted below eGFR 45, but the cardiovascular, heart-failure, and kidney benefits persist. Expect a small reversible creatinine rise and counsel on genital hygiene and sick-day rules.
2. Reduce metformin to 500 mg twice daily. At eGFR 30–45, continuing full-dose metformin raises the risk of lactic acidosis, and maximum dosing should be about 1000 mg/day. Do not stop it entirely unless eGFR falls below 30, and hold it during acute illness or contrast exposure.
3. Add a GLP-1 receptor agonist with proven cardiovascular benefit (e.g., semaglutide), or basal insulin if cost or access blocks it. The GLP-1 agonist addresses his A1c, his obesity, and his atherosclerotic risk simultaneously and is the natural answer to his request for "a stronger pill" - the injection objection can be reframed by demonstrating a pen.
Also ensure the statin is high intensity (atorvastatin 40–80 mg) and the ACE inhibitor is at the maximum tolerated dose; if albuminuria persists with normal potassium, finerenone is a further option.
2. What HbA1c target would you set, and what monitoring does he need now that his regimen is changing?
Read the worked answer
Target approximately 7.5–8.0%, not 6.5%. He has established cardiovascular disease, CKD 3b, and a long duration of diabetes, so the expected benefit of near-normal glycemia is small while the risk of hypoglycemia and polypharmacy is real. Reducing from 9.3% toward 8% captures most of the microvascular benefit; weight and cardiorenal risk factor control matter more than the last percentage point.
Monitoring:
- Basic metabolic panel including potassium and creatinine in 2–4 weeks after starting the SGLT2 inhibitor and after any ACE inhibitor or diuretic change.
- HbA1c every 3 months until stable, then every 6 months.
- Urine albumin-to-creatinine ratio annually, plus lipids and blood pressure at each visit.
- Symptoms of euglycemic ketoacidosis and instructions to hold the SGLT2 inhibitor for 3–4 days before surgery, with acute illness, or during prolonged fasting.
- Annual dilated eye exam, foot exam at every visit, and vitamin B12 if metformin continues long term.
He needs no sulfonylurea: in CKD, hypoglycemia risk is high and it does nothing for his cardiorenal risk.
3. He returns 3 months later with HbA1c 8.4%, BP 138/84 mmHg, potassium 4.5 mEq/L, and persistent albuminuria. He has lost 4 kg. What is your next step and why?
Read the worked answer
He is moving in the right direction; intensify without destabilizing what is working.
- A1c 8.4% with 4 kg weight loss: the GLP-1 agonist is working but not fully titrated. Increase to the maximum tolerated dose before adding basal insulin. If A1c remains above 8% after titration, add basal insulin at 10 units daily or 0.1–0.2 units/kg, titrating to fasting glucose 80–130 mg/dL, and consider stopping metformin if he prefers fewer tablets.
- Persistent albuminuria with potassium 4.5 and eGFR 42: first confirm the ACE inhibitor is at the maximum tolerated dose; if albuminuria remains above 300 mg/g, add finerenone and recheck potassium and creatinine at 1 month. Do not combine an ACE inhibitor with an ARB.
- BP 138/84: goal is below 130/80 in this population; uptitrate the ACE inhibitor or add a thiazide-like diuretic or amlodipine, monitoring potassium.
- Keep the SGLT2 inhibitor and statin unchanged - they are the therapies most likely to change his long-term renal and cardiovascular trajectory, and neither should be adjusted because of a modest A1c shortfall.